Shots:

• Pregene to receive $5M upfront and milestone for the 1^st indication and $7.5M milestone for subsequent indications and is also eligible to receive $150M royalty on future sales of PRG1801 in the licensed countries
• Dr. Reddy's will acquire the exclusive rights to commercialize PRG1801 in India and will be responsible for future development including clinical trials. Pregene will be the exclusive supplier of the lentiviral vectors for manufacturing PRG1801 and retain global rights outside of India- except China
• PRG1801 is an anti-BCMA CAR-T therapy for the treatment of r/rMM which demonstrates efficacy and safety profile in 34 patients in an investigator-initiated trial in China

  Ref: Dr Reddy | Image: Dr Reddy